Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update
by Teresa Graham · The Cerbat GemInventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 115,672 shares, an increase of 32.9% from the December 15th total of 87,064 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 217,009 shares, the short-interest ratio is currently 0.5 days. Based on an average daily volume of 217,009 shares, the short-interest ratio is currently 0.5 days. Approximately 0.1% of the company’s shares are sold short.
Institutional Investors Weigh In On Inventiva
A number of large investors have recently modified their holdings of IVA. Millennium Management LLC acquired a new position in Inventiva during the 3rd quarter worth approximately $649,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares during the period. NewEdge Advisors LLC acquired a new position in shares of Inventiva during the third quarter worth $116,000. Finally, Creative Planning purchased a new position in shares of Inventiva in the second quarter valued at $32,000. Institutional investors and hedge funds own 19.06% of the company’s stock.
Inventiva Price Performance
Shares of Inventiva stock traded up $0.39 during trading hours on Monday, hitting $6.51. The company’s stock had a trading volume of 387,465 shares, compared to its average volume of 386,740. The business has a fifty day moving average of $4.51 and a 200 day moving average of $4.58. Inventiva has a 1-year low of $2.11 and a 1-year high of $7.98.
Analyst Ratings Changes
Several analysts have commented on IVA shares. Wall Street Zen upgraded Inventiva to a “hold” rating in a report on Saturday, October 18th. Leerink Partners started coverage on shares of Inventiva in a research report on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price on the stock. Leerink Partnrs upgraded shares of Inventiva to a “strong-buy” rating in a report on Monday, January 12th. HC Wainwright upped their price target on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of Inventiva in a research note on Tuesday, September 30th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Inventiva presently has an average rating of “Buy” and an average price target of $16.00.
View Our Latest Analysis on IVA
Inventiva Company Profile
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.